| ABC | ATP-binding cassette | 18F-FLT | 18F-fluorothymidine | NSCLC | non-small cell lung carcinoma |
| Akt | protein kinase B | FGF | fibroblast growth factor | Oct-4 | octamer binding protein 4 |
| ALDH | enzyme aldehyde dehydrogenase |
FOXO | forkhead Box class O | OER | oxygen enhancement ratio |
| APLN | angiopoietins, ephrins, apelin | γ-H2AX | phosphorylated Histone 2AX | PDGF | platelet-derived growth factor |
| ATM | ataxia-telangiectasia mutated | GS | γ secretase | PET | positron emission tomography |
| ATR | ataxia telangiectasia and Rad3-related protein | GSIs | γ-secretase inhibitors | PlGF | placental growth factor |
| Bcl-2 | B-cell lymphoma 2 | GSK-3β | glycogen synthase kinase 3 beta | PTEN | phosphatase and tensin homolog |
| BCSC | breast cancer stem cells | HDAC | histone deacetylases | PI3K | phosphatidylinositol 3-kinase |
| BSO | buthionine ulfoximine | HGF | hepatocyte growth factor | RAD51 | |
| CAFs | cancer-associated fibroblasts | Hh | hedgehog signaling | ROS | reactive oxygen species |
| CAIX | carbonic anhydrase IX | HIF1a | hypoxia-inducible factor-1a | RBE | relative biological effectiveness |
| CDC20 | cell-division cycle protein 20 | HR | homologous repair | ROS | reactive oxygen species |
| CD133 | prominin I | ICB | immune checkpoint blockade | RT | radiotherapy |
| CHART | continuous hyperfractionated accelerated radiotherapy trial | ICIs | immune checkpoint inhibitors | SBRT | stereotactic body radiation therapy |
| chks | checkpoints | IL1β | interleukine 1β | SSEA | stage-specific embryonic antigen |
| CHK1 | checkpoint kinase 1 | IL4 | interleukine 4 | SP | side population |
| CHK2 | checkpoint kinase 2 | IL6 | interleukine 6 | TAMs | tumor-associated macrophages |
| CSC | cancer stem cells | IL8 | interleukine 8 | TANs | tumor-associated neutrophils |
| CTC | circulating tumor cells | IL10 | interleukine 10 | TIMPs | endogenous metalloproteinase inhibitors |
| CXC | C-X-C motif chemokines | LET | linear energy transfer | TGF-ß | transforming growth factor-ß |
| CXCL12 C-X-C |
motif chemokine ligand 12 | M1 | classically activated macrophage | TGF-ß1 | transforming growth factor-ß1 |
| DAHANCA | Danish Head and Neck Cancer trial | M2 | alternatively activated macrophage | TNF-α | tumor necrosis factor-alpha |
| DAMPs | damage associated molecular patterns |
MDSC | myeloid-derived suppressor cells | TICs | tumor initiating cells |
| DCA | dichloroacetate | MiRNAs | microRNAs | TME | tumor microenvironment |
| DDR | DNA damage response | MMPs | matrix metalloproteases | TRAIL | Fas receptor and TNF-related apoptosis inducing ligand |
| DNA | deoxyribonucleic Acid | mRNA | messenger RNA | Treg | regulatory T cells |
| DNA-PKc | DNA-dependent protein kinase, catalytic subunit | mTOR | mammalian target of rapamycin | TSCs | tumor stem cells |
| DSBs | double-strand breaks | NFκB | nuclear factor-κB | UPR | unfolded protein response |
| ECM | extracellular matrix | NHEJ | non-homologous end joining | UV | ultraviolet |
| EGF | epidermal growth factor | NRF2 | nuclear factor-erythroid 2 p45-related factor 2 | VEGF | vascular endothelial growth factor |
| EMT | epithelial-mesenchymal transition | NOD/SCID | nonobese diabetic/severe combined immunodeficient | Wnt | wingless/integrated |